Sökning: WFRF:(Fei Mingwei) > (2019) > Effect of Condition...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05010naa a2200853 4500 | |
001 | oai:DiVA.org:uu-374009 | |
003 | SwePub | |
008 | 190117s2019 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:140781150 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3740092 URI |
024 | 7 | a https://doi.org/10.1016/j.bbmt.2018.11.0052 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1407811502 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Brunstein, Claudio G4 aut |
245 | 1 0 | a Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation |
264 | 1 | b Elsevier BV,c 2019 |
338 | a print2 rdacarrier | |
520 | a Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index (BMI) ≥ 30 kg/m2. Dose adjustment was defined as a reduction in standard dosing ≥ 20%, based on ideal, reported dosing and actual weights. We included 2 groups of US patients who had received autoHCT between 2008 and 2014. Specifically, we included patients with multiple myeloma (MM, n = 1696) treated with high-dose melphalan and patients with Hodgkin or non-Hodgkin lymphomas (n = 781) who received carmustine, etoposide, cytarabine, and melphalan conditioning. Chemotherapy dose was adjusted in 1324 patients (78%) with MM and 608 patients (78%) with lymphoma. Age, sex, BMI, race, performance score, comorbidity index, and disease features (stage at diagnosis, disease status, and time to transplant) were similar between dose groups. In multivariate analyses for MM, adjusting for melphalan dose and for center effect had no impact on overall survival (P = .894) and treatment-related mortality (TRM) (P = .62), progression (P = .12), and progression-free survival (PFS; P = .178). In multivariate analyses for lymphoma, adjusting chemotherapy doses did not affect survival (P = .176), TRM (P = .802), relapse (P = .633), or PFS (P = .812). No center effect was observed in lymphoma. This study demonstrates that adjusting chemotherapy dose before autoHCT in obese patients with MM and lymphoma does not influence mortality. These results do not support adjusting chemotherapy dose in this population. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
653 | a Autologous hematopoietic cell transplantation | |
653 | a Conditioning regimen | |
653 | a Obesity | |
700 | 1 | a Pasquini, Marcelo C4 aut |
700 | 1 | a Kim, Soyoung4 aut |
700 | 1 | a Fei, Mingwei4 aut |
700 | 1 | a Adekola, Kehinde4 aut |
700 | 1 | a Ahmed, Ibrahim4 aut |
700 | 1 | a Aljurf, Mahmoud4 aut |
700 | 1 | a Agrawal, Vaibhav4 aut |
700 | 1 | a Auletta, Jeffrey J4 aut |
700 | 1 | a Battiwalla, Minoo4 aut |
700 | 1 | a Bejanyan, Nelli4 aut |
700 | 1 | a Bubalo, Joseph4 aut |
700 | 1 | a Cerny, Jan4 aut |
700 | 1 | a Chee, Lynette4 aut |
700 | 1 | a Ciurea, Stefan O4 aut |
700 | 1 | a Freytes, Cesar4 aut |
700 | 1 | a Gadalla, Shahinaz M4 aut |
700 | 1 | a Gale, Robert Peter4 aut |
700 | 1 | a Ganguly, Siddhartha4 aut |
700 | 1 | a Hashmi, Shahrukh K4 aut |
700 | 1 | a Hematti, Peiman4 aut |
700 | 1 | a Hildebrandt, Gerhard4 aut |
700 | 1 | a Holmberg, Leona A4 aut |
700 | 1 | a Lahoud, Oscar B4 aut |
700 | 1 | a Landau, Heather4 aut |
700 | 1 | a Lazarus, Hillard M4 aut |
700 | 1 | a de Lima, Marcos4 aut |
700 | 1 | a Mathews, Vikram4 aut |
700 | 1 | a Maziarz, Richard4 aut |
700 | 1 | a Nishihori, Taiga4 aut |
700 | 1 | a Norkin, Maxim4 aut |
700 | 1 | a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD)4 aut0 (Swepub:uu)riols677 |
700 | 1 | a Reshef, Ran4 aut |
700 | 1 | a Rotz, Seth4 aut |
700 | 1 | a Savani, Bipin4 aut |
700 | 1 | a Schouten, Harry C4 aut |
700 | 1 | a Seo, Sachiko4 aut |
700 | 1 | a Wirk, Baldeep M4 aut |
700 | 1 | a Yared, Jean4 aut |
700 | 1 | a Mineishi, Shin4 aut |
700 | 1 | a Rogosheske, John4 aut |
700 | 1 | a Perales, Miguel-Angel4 aut |
710 | 2 | a Uppsala universitetb Centrum för klinisk forskning i Sörmland (CKFD)4 org |
773 | 0 | t Biology of blood and marrow transplantationd : Elsevier BVg 25:3, s. 480-487q 25:3<480-487x 1083-8791x 1523-6536 |
856 | 4 | u http://www.bbmt.org/article/S1083879118306992/pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-374009 |
856 | 4 8 | u https://doi.org/10.1016/j.bbmt.2018.11.005 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:140781150 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.